An innovative high capacity Accordion bioreactor technology for high performance...
An innovative high capacity Accordion bioreactor technology for high performance and low cost microalgae production
Access to vital raw ingredients for food/feed production is an increasing challenge in several industries. Biopharmia is a Norwegian company focusing on cultivation of microalgae through its development of a proprietary bioreactor...
ver más
30/04/2017
Biopharmia AS
71K€
Presupuesto del proyecto: 71K€
Líder del proyecto
BIOPHARMIA AS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite participación
Sin fecha límite de participación.
Financiación
concedida
El organismo H2020 notifico la concesión del proyecto
el día 2017-04-30
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto Accordion Bioreactor
Duración del proyecto: 5 meses
Fecha Inicio: 2016-11-28
Fecha Fin: 2017-04-30
Líder del proyecto
BIOPHARMIA AS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Access to vital raw ingredients for food/feed production is an increasing challenge in several industries. Biopharmia is a Norwegian company focusing on cultivation of microalgae through its development of a proprietary bioreactor. Through years of expertise and collaborations with experts in the field of microalgae growth, Biopharmia have developed and patented the Accordion bioreactor, a proven and efficient platform for industrial scale production of high quality microalgae, at lower energy and decreased production cost, compared to other solutions. This technology aims to strengthen Europe’s position in the microalgae market, which is currently weak due to cheaper, low quality foreign competitors. The technology describes the unique wave configuration comprising the frame work of the bioreactor, which contributes to higher productivity and lower cost of production and investment when compared to competing technologies. The modular design of this closed system greatly minimises the risk of contamination and can be easily adapted to large scale production. Biopharmia need to undertake the proposed innovation project to develop and further test the Accordion technology with multiple algae strains. The company has a close collaboration with the University of Arizona (UA) and has demonstrated the efficiency and productivity of its bioreactors through extensive testing at UA. Biopharmia has supplied biomass to a number of entities in Norway with very good results. Biopharmia has Letters of Intent about supply of biomass to two Norwegian customers in different segments, food supplements and aquaculture. In 2012 the company raised €1 million in private venture capital from IFE Venture. Biopharmia intends to establish initial production using the Accordion technology for the clients the company have an LOI with before expanding production.